The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn’t ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company ...

Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the povorcitinib/povo Phase3 results in moderate to severe hidradenitis ...

Shares of Incyte Corp. slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the stock ...

Incyte (NASDAQ:INCY – Free Report) had its price target reduced by Truist Financial from $74.00 to $72.00 in a report issued on Tuesday,Benzinga reports. They currently have a hold rating on the ...

Incyte (INCY – Research Report) received a Hold rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...

Guggenheim lowered shares of Incyte (NASDAQ:INCY – Free Report) from a buy rating to a neutral rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have $92.00 price ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Hold rating on Incyte (INCY – Research Report), with a ...

U.S. equities were mixed at midday, with positive news on retail sales eased continuing concerns about tariffs.

The latest international Siddhi Mahatole news and views from Reuters - one of the world's largest news agencies ...

The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...